Download Supersaturated Oxygen: Key To Prevent Permanent Heart Attack

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Remote ischemic conditioning wikipedia , lookup

Electrocardiography wikipedia , lookup

Heart failure wikipedia , lookup

Lutembacher's syndrome wikipedia , lookup

Angina wikipedia , lookup

Cardiac contractility modulation wikipedia , lookup

Drug-eluting stent wikipedia , lookup

Antihypertensive drug wikipedia , lookup

Quantium Medical Cardiac Output wikipedia , lookup

History of invasive and interventional cardiology wikipedia , lookup

Management of acute coronary syndrome wikipedia , lookup

Heart arrhythmia wikipedia , lookup

Coronary artery disease wikipedia , lookup

Dextro-Transposition of the great arteries wikipedia , lookup

Transcript
Supersaturated Oxygen: Key To Prevent Permanent
Heart Attack Damage?
February 17, 2013 6:23 PM
CBS Detroit
ROYAL OAK — Over the past two decades, cardiologists have explored many different treatments to help
prevent permanent heart damage after a heart attack.
One treatment that appears to be very promising is supersaturated oxygen — a therapy based on the known
benefits of hyperbaric oxygen treatment in patients with burns and wounds.
Developed in Detroit, SSO2 Therapy is the equivalent of a hyperbaric oxygen chamber for the heart.
Beaumont has been one of the few centers in the U.S. pioneering SSO2 Therapy and is now leading a new
clinical research study involving four sites to test the effectiveness of this novel treatment.
Michael King, 58, a banker who lives in Birmingham, was the second patient to participate in the new research
study.
King was at home on a Saturday morning preparing for the delivery of new furniture when he started having
throbbing pain in his chest and arm.
“Like any guy, I thought I could man up and get through it,” he said.
But his wife thought better. She called an ambulance. Within minutes, he was transported to Beaumont, Royal
Oak’s Emergency Center. In no more than an hour, he was in the catheterization lab being treated for a
blockage in the left anterior descending artery of his heart — the artery often called the “widowmaker.” He was
treated with angioplasty and three coronary artery stents.
When presented with the option of participating in the SSO2 Therapy research trial, he recalls thinking, “If this
is on the leading edge, I am in for it.”
“Everyone gave me a lot of really great information about the treatment and the process,” he says. “I don’t
remember much. It seemed to be over in the blink of an eye.”
A heart attack is caused by a sudden blockage in one of the coronary arteries that supply the heart muscle with
oxygen. This interruption in blood flow causes the muscle cells to die which may weaken the pumping ability of
the heart, resulting in congestive heart failure or death.
Emergency angioplasty and stenting is the most effective way to relieve a heart blockage and stop a heart
attack. In angioplasty, a hollow tube called a catheter is inserted into arteries in the groin or arm and threaded
into the heart where a balloon is inflated to open the heart blockage. A wire mesh device called a stent is then
placed at the site of the blockage as a “scaffold” to prop the artery open.
The faster the blocked artery is opened the better, since muscle damage occurs when the heart is starved of
blood flow. The amount of muscle damage is the most important factor influencing a patient’s recovery and
future well being.
In the Beaumont research study, SSO2 Therapy is delivered after the physician has treated the artery with a
stent. Using a small circuit, the patient’s blood is supersaturated with oxygen and then returned directly into the
main heart artery through a small catheter for 60 minutes.
“The high level of oxygen appears to improve healing, and in previous studies has been shown to reduce the
size of the heart attack by 25 percent, says Simon Dixon, M.D., principal investigator and chair of Beaumont
Health System’s department of Cardiovascular Medicine.
SSO2 therapy is not approved by the Food and Drug Administration at this time and may not be suitable for all
heart attack patients.
“However, for those with large heart attacks, the treatment looks promising,” says Dr. Dixon.
For more information about the study, call (248) 898-0315.